Residual Myocardial Iron Following Intramyocardial Hemorrhage During the Convalescent Phase of Reperfused ST-Segment–Elevation Myocardial Infarction and Adverse Left Ventricular Remodeling

Heerajnarain Bulluck, MBBS; Stefania Rosmini, MD, PhD; Amna Abdel-Gadir, MBBS; Steven K. White, MBChB; Anish N. Bhuva, MBBS; Thomas A. Treibel, MBBS; Marianna Fontana, MD, PhD; Manish Ramlall, MBChB; Ashraf Hamarneh, MBBS; Alex Sirker, PhD; Anna S. Herrey, MD, PhD; Charlotte Manisty, PhD; Derek M. Yellon, MSc, PhD; Peter Kellman, PhD; James C. Moon, MD; Derek J. Hausenloy, PhD

Background—The presence of intramyocardial hemorrhage (IMH) in ST-segment–elevation myocardial infarction patients reperfused by primary percutaneous coronary intervention has been associated with residual myocardial iron at follow-up, and its impact on adverse left ventricular (LV) remodeling is incompletely understood and is investigated here.

Methods and Results—Forty-eight ST-segment–elevation myocardial infarction patients underwent cardiovascular magnetic resonance at 4±2 days post primary percutaneous coronary intervention, of whom 40 had a follow-up scan at 5±2 months. Native T1, T2, and T2* maps were acquired. Eight out of 40 (20%) patients developed adverse LV remodeling. A subset of 28 patients had matching T2* maps, of which 15/28 patients (54%) had IMH. Eighteen of 28 (64%) patients had microvascular obstruction on the acute scan, of whom 15/18 (83%) patients had microvascular obstruction with IMH. On the follow-up scan, 13/15 patients (87%) had evidence of residual iron within the infarct zone. Patients with residual iron had higher T2 in the infarct zone surrounding the residual iron when compared with those without. In patients with adverse LV remodeling, T2 in the infarct zone surrounding the residual iron was also higher than in those without (60 [54–64] ms versus 53 [51–56] ms; P=0.025). Acute myocardial infarct size, extent of microvascular obstruction, and IMH correlated with the change in LV end-diastolic volume (Pearson’s rho of 0.64, 0.59, and 0.66, respectively; P=0.18 and 0.62, respectively, for correlation coefficient comparison) and performed equally well on receiver operating characteristic curve for predicting adverse LV remodeling (area under the curve: 0.99, 0.94, and 0.95, respectively; P=0.19 for receiver operating characteristic curve comparison).

Conclusions—The majority of ST-segment–elevation myocardial infarction patients with IMH had residual myocardial iron at follow-up. This was associated with persistently elevated T2 values in the surrounding infarct tissue and adverse LV remodeling. IMH and residual myocardial iron may be potential therapeutic targets for preventing adverse LV remodeling in reperfused ST-segment–elevation myocardial infarction patients. (Circ Cardiovasc Imaging. 2016;9:e004940. DOI: 10.1161/CIRCIMAGING.116.004940.)

Key Words: cardiovascular magnetic resonance ▪ microvascular obstruction ▪ intramyocardial hemorrhage ▪ residual myocardial iron ▪ ST-segment–elevation myocardial infarction ▪ T2 mapping ▪ T2* mapping
and ≈40% of STEMI patients develop intramyocardial hemorrhage (IMH) detected by cardiovascular magnetic resonance (CMR). Both MVO and IMH are associated with larger myocardial infarct (MI) size, adverse left ventricular (LV) remodeling, and worse clinical outcomes.4-11

LV remodeling post MI refers to the intricate changes that occur in both the infarcted and remote myocardium on a molecular, structural, geometric, and functional level, and its occurrence predisposes to heart failure. The 3 partially overlapping phases during post MI LV remodeling are the inflammatory phase, the proliferative phase, and the maturation phase.12 Numerous anti-inflammatory agents, such as glucocorticoids, monoclonal antibodies, C1 esterase inhibitors, metalloproteinase inhibitors, phosphoinositide-3-kinase inhibitors, and immunoglobulin, have had promising results in the experimental setting, but have failed to translate into the clinical setting.14

Therefore, new therapeutic targets are required to prevent adverse LV remodeling and to improve clinical outcomes in reperfused STEMI patients. IMH and its iron degradation products have been shown to result in residual myocardial iron within the MI zone and have been proposed to have cytotoxic and proinflammatory effects on the myocardium.15,16 In some STEMI patients, areas of T2 abnormalities within the infarct zone have been shown to persist on CMR performed 6 months post PPCI.17,18 The pathogenesis of the persistently elevated T2 signal and its relationship to adverse LV remodeling remains to be determined.

Therefore, we hypothesized that patients with adverse LV remodeling were more likely to (1) have MVO/IMH on the acute scan; (2) have residual myocardial iron at follow-up; and (3) have persistently elevated T2 values in surrounding areas of residual myocardial iron that may be suggestive of persistent myocardial inflammation.

### Methods

#### Study Population

Fifty STEMI patients reperfused by PPCI were prospectively recruited between August 2013 and July 2014. The main exclusion criteria were previous MI and standard recognized contraindications to CMR, such as estimated glomerular filtration rate <30 mL/min, ferromagnetic implants, and claustrophobia. The acute CMR scan was performed at 4±2 days post STEMI and a follow-up CMR scan at 5±2 months. The UK National Research Ethics Service approved this study, and all patients provided written informed consent.

#### CMR Acquisition

CMR was performed on a 1.5 Tesla scanner (Magnetom Avanto; Siemens Medical Solutions) using a 32-channel phased-array cardiac coil. The imaging protocol included balanced steady-state free precession cines, native T1, T2, and T2* mapping (Work In Progress 448b; Siemens Healthcare), and late gadolinium enhancement (LGE) LV short-axis images. For the acute scan, whole LV short-axis coverage for T1 and T2 maps and 3 (basal, mid, and apical) LV short-axis slices T2* maps were acquired. On the follow-up scan, only basal, mid, and apical short-axis slices were acquired for native T1, T2, and T2* maps.

#### Native T1 Mapping

Native T1 maps were acquired with a steady-state free precession–based Modified Look-Locker Inversion Recovery (MOLLI) sequence using a 5s(3s)3s modified sampling protocol. The acquisition parameters were flip angle = 35°; pixel bandwidth = 977 Hz/pixel; matrix = 256×144; echo time = 1.1 ms; and slice thickness = 6 mm. A pixel-wise colored T1 map was generated after performing motion correction and a nonlinear least-square curve fitting of the set of images acquired at different inversion times.
Bulluck et al  Residual Iron in STEMI and Adverse LV Remodeling

T2 Mapping
Colored T2 maps consisting of pixel-wise T2 values were generated inline after motion correction and fitting to estimate T2 relaxation times after acquiring 3 single-shot images at different T2 preparation times (0, 24, and 55 ms, respectively). The acquisition parameters were flip angle = 70°; pixel bandwidth = 930 Hz/pixel; matrix = 116×192; echo time = 1.1 ms; repetition time = 3×R-R interval; and slice thickness = 6 mm.

T2* Mapping
T2* maps were obtained using the following imaging parameters: bandwidth 814(×8) Hz/pixel; echo times×8: 2.7, 5, 7.3, 9.6, 11.9, 14.2, 16.5, and 18.8 ms; flip angle = 18°; acquisition matrix = 256×115; and slice thickness = 8 mm. A colored pixel-wise T2* map was generated by the scanner.

Late Gadolinium Enhancement
LGE images were acquired 10 to 15 minutes after the injection of 0.1 mmol/kg of gadoterate meglumine (Gd-DOTA marketed as Dotarem; Guerbet S.A., Paris, France), using either a standard segmented fast low-angle shot 2-dimensional inversion-recovery gradient echo sequence (n=16) or a respiratory motion-corrected, free-breathing single-shot steady-state free precession averaged phase-sensitive inversion recovery sequence (n=24).

Figure 1 shows an example of the basal short axis images acquired during the acute scan and at follow-up in a patient with an inferior STEMI.

CMR Analysis
Imaging analysis was performed using CVI42 software (Version 5.1.2[303], Calgary, Canada).

Adverse LV remodeling was defined as a ≥20% increase in LV end-diastolic volume (EDV) between the acute and follow-up scans.22 MI size was quantified in grams and as a percentage of the LV (%LV) using a signal-intensity threshold of 5 standard deviations (SD) above the mean remote myocardium. The area at risk (AAR) was assessed from the T2 maps using a signal intensity threshold of 2SD above the mean remote myocardium and expressed as %LV. The presence of MVO (late MVO) was defined as areas of hypoenhancement on the LGE images and was quantified and expressed as %LV. Areas of MVO were included as part of the MI zone and AAR.

Figure 2. Method used to detect the area of high T2 (T2_infarct) around the area of residual myocardial iron (T2_core) and the remote myocardium (T2_remote) using a threshold of 2 standard deviation (SD) from the remote myocardium. LGE indicates late gadolinium enhancement.
A hypointense core on the T2* maps with a T2* value of <20 ms was used to identify the presence of IMH on the acute scans and residual myocardial iron on the follow-up scans.24–28 The extent of IMH and residual iron was quantified using manual region of interest (ROI) delineation around the hypointense core on the basal, mid, and apical slices and expressed as %LV.

For the follow-up T1 and T2 maps, a ROI was manually drawn in hyperenhanced area using a signal intensity threshold of 2SD from the remote myocardium (using the LGE images as reference) and was denoted as T1Infarct and T2Infarct, respectively.

A second ROI was copied from the hypointense core of the T2* map onto the T1 and T2 maps and denoted as T1Core and T2Core as illustrated in Figure 2.

In cases when there were no areas of hyperenhancement on the follow-up maps using a 2SD threshold, an ROI from the areas of LGE was copied on to the maps for representative values. An ROI was also drawn in the remote myocardium and expressed as T1Remote and T2Remote.

### Statistical Analysis
Statistical analysis was performed using SPSS version 22 (IBM Corporation, IL). Continuous data were expressed as mean±SD or median (interquartile range), and categorical data were reported as frequencies and percentages. Normality was assessed using Shapiro–Wilks test. Independent groups (those with and without IMH; with and without paired CMR scans; with and without residual iron at follow-up; with and without adverse LV remodeling; without adverse LV remodeling but with and without residual iron) were compared with unpaired Student’s t test for normally distributed data and with Mann–Whitney U test for non-normally distributed data. Comparison between paired acute and follow-up scan was performed using paired Student’s t test for normally distributed data and Wilcoxon signed-rank test for non-normally distributed data. To compare T1 and T2 values in the remote, core, and infarct territories between patients and divided between those with and without residual iron, a linear mixed model was used, with the patients as a random factor and the territory within the patients (remote, core, and infarct) being a fixed factor. Comparisons of 3 independent groups (no residual iron, residual iron only, and residual iron and adverse LV remodeling) was performed using Kruskal–Wallis Test and post hoc pairwise comparisons. Categorically variables such as incidence of MVO or IMH were compared using chi-squared test or Fisher exact test. Pearson rho correlation coefficient was assessed between MVO, acute MI size, IMH, and adverse LV remodeling as a continuous variable, respectively, and their correlations were compared. Receiver operating characteristic curve was also used to compare the diagnostic performance of MVO, acute MI size, and IMH to predict adverse LV remodeling. All statistical tests were 2-tailed, and P<0.05 was considered statistically significant.

### Results
Out of 50 STEMI patients recruited into the study, 48 STEMI patients (mean age 59±13 years old, 88% male) completed the acute scan at 4±2 days post PPCI, and 40 of these patients had a follow-up scan at 5±2 months. Two patients did not complete the scans because of unexpected claustrophobia. Characteristics of the 40 patients with a follow-up scan included in this study are listed in Table 1. CMR details of these 40 patients are shown in Table 2. A CONSORT (Consolidated Standards of Reporting Trials) flow diagram is provided in the Data Supplement. The median chest pain onset to PPCI time was 267 (122–330) minutes. No patients had heart failure at baseline. The MI size was 27.4±14.6 %LV, and T2-based AAR was 42.7±11.9 %LV. MVO was present in 65% (26/40) of patients (mean MVO size of 13.6±7.2 %LV). In 24% of scans, the T2* maps (acute and follow-up) had to be excluded because they were not interpretable because of motion and off-resonance artifacts. After a mean follow-up of 5±2 months, 2 patients were rehospitalized for heart failure, and there were no deaths.

### IMH and Edema-Based AAR
Patients with IMH had lower T2 Core (50 [46–53] ms versus 55 [52–59] ms; P=0.001) but similar T2 Infarct (64 [62–64] ms versus 64 [62–69] ms; P=0.29) and T2 in the salvaged myocardium (65 [61–68] ms versus 63 [62–67] ms; P=0.43). However, in patients with IMH, edema-based AAR was larger (46 [40–55] %LV versus 31 [24–43] %LV; P=0.009) and

<table>
<thead>
<tr>
<th>Details</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>40</td>
</tr>
<tr>
<td>Male (%)</td>
<td>35 (88%)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>59±13</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>8 (20%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>14 (35%)</td>
</tr>
<tr>
<td>Smoking</td>
<td>12 (30%)</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>14 (35%)</td>
</tr>
<tr>
<td>Heart failure at baseline</td>
<td>0</td>
</tr>
<tr>
<td>Chest pain onset to PPCI (minutes)</td>
<td>267 (122–330)</td>
</tr>
<tr>
<td>Infarct artery (%)</td>
<td></td>
</tr>
<tr>
<td>LAD</td>
<td>24 (60%)</td>
</tr>
<tr>
<td>RCA</td>
<td>14 (35%)</td>
</tr>
<tr>
<td>Cx</td>
<td>2 (5%)</td>
</tr>
<tr>
<td>Treatment: on discharge</td>
<td></td>
</tr>
<tr>
<td>Dual antiplatelet therapy</td>
<td>40 (100%)</td>
</tr>
<tr>
<td>Beta blockers</td>
<td>40 (100%)</td>
</tr>
<tr>
<td>ACEI/ARB</td>
<td>40 (100%)</td>
</tr>
<tr>
<td>Statin</td>
<td>39 (98%)</td>
</tr>
<tr>
<td>MRA</td>
<td>10 (25%)</td>
</tr>
</tbody>
</table>

ACEI/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; Cx, circumflex artery; LAD, left anterior descending artery; MRA, mineralocorticoid receptor antagonist; PPCI, primary percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment-elevation myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction.
myocardial salvage index was smaller (0.24 [0.16–0.43] versus 0.61 [0.36–0.88]; \( P = 0.009 \)), when compared with those without IMH.

### Residual Myocardial Iron on the Follow-Up Scan in a Subset of Patients

A subset of 28 patients who completed the follow-up scans had matching and interpretable T2* maps. There was no difference in the CMR parameters between those with paired T2* maps (n=28) and those without (n=12; see Table in the Data Supplement). On the acute scan, 15/28 (54%) patients had IMH and 18/28 (64%) had MVO. Fifteen of 18 (83%) patients had MVO with IMH. On the follow-up scan, 13/15 (87%) patients had evidence of residual myocardial iron.

### T1 and T2 of the Core, Infarct Zone, and Remote Myocardium at Follow-Up

Using a linear mixed model to adjust for within-patient interaction, in patients without residual myocardial iron, there was no difference between T1\_core and T1\_infarct \( (1042 \text{ [1015–1140]} \text{ ms versus 1113 [1092–1140]} \text{ ms}; \ P = 0.20 \), and T1\_infarct was significantly higher than T1\_Remote \( (1113 \text{ ms versus 1007 [966–1039]} \text{ ms}; \ P = 0.001 \).
However, T2_{Core} was lower than T2_{Infarct} (47 [45–49] ms versus 53 [51–55] ms; P=0.001) and similar to T2_{Remote} (47 [45–49] ms versus 47 [45–48] ms; P=1.0), and T2_{Infarct} was significantly higher than T2_{Remote} (53 [51–55] ms versus 47 [45–48] ms; P<0.001; Figure 3).

In patients with residual myocardial iron, both T1_{Core} and T2_{Core} were similar to T1_{Remote} and T2_{Remote} (T1: 1004 [90–1028] ms versus 1015 [989–1020] ms; P=1.0; T2: 47 [45–50] ms versus 49 [46–51] ms; P=1.0) but significantly lower than T1_{Infarct} and T2_{Infarct} (T1: 1004 [90–1028] ms versus 1162 [1132–1216] ms; P<0.001; T2: 47 [45–50] ms versus 60 [58–64] ms; P<0.001) respectively (Figure 3).

Patients with residual myocardial iron had lower T1_{Core}, similar T2_{Core}, and higher T1_{Infarct} and T2_{Infarct} when compared with patients without. There was no difference in the T1_{Remote} and T2_{Remote} between these 2 groups as illustrated in Figure 3.

Figure 4 shows an example of 3 patients with acute and follow-up CMR images showing MVO, IMH, residual myocardial iron, and persistently elevated T2 in the surrounding myocardium within the infarct zone at follow-up.

**Residual Myocardial Iron and Adverse LV Remodeling**

In patients with adverse LV remodeling, T2_{Infarct} was significantly higher than in those without adverse LV remodeling and without residual myocardial iron (60 [54–64] ms versus 53 [51–56] ms; P=0.025), but similar to those with residual myocardial iron but no adverse LV remodeling (60 [54–64] ms versus 60 [58–63] ms; P=1.0) as shown in Figure 5A.

However, when looking at those patients who did not develop adverse LV remodeling, those with residual iron had a significantly higher change in EDV (8% [−2% to 14%] versus −4% [−7% to 5%]; P=0.043) when compared with those patients without residual myocardial iron (Figure 5B).

**Relationship Between Acute MI Size, MVO, and IMH and Adverse LV Remodeling**

Acute MI size, extent of MVO, and IMH correlated with the change in LV EDV (Pearson’s rho of 0.64, 0.59, and 0.66, respectively; P values of 0.18 and 0.62, respectively, for correlation coefficient comparison) and performed equally well on receiver operating characteristic curve for predicting adverse LV remodeling (area under the curve: 0.99, 0.94, and 0.95, respectively, P=0.19 for receiver operating characteristic curve comparison).

**Discussion**

The major findings of our study are as follows: (1) the majority of STEMI patients treated by PPCI with MVO also had IMH (83%); (2) many of these patients with IMH had residual myocardial iron at follow-up (87%), and these patients had elevated T2 values on CMR in the surrounding myocardium in the MI zone, suggestive of delayed...
resolution of edema or inflammation; (3) all patients with adverse LV remodeling had residual myocardial iron and elevated T2 in the surrounding myocardium in the MI zone; and (4) acute MI size, the extent of MVO, and IMH correlated equally well with the change in LV EDV and performed with high diagnostic accuracy to predict adverse LV remodeling.

Furthermore, in patients not meeting the definition for adverse LV remodeling, those with residual myocardial iron had a larger percentage increase in EDV than those without residual myocardial iron, confirming an overlap between the inflammatory phase and proliferation phase previously described. Although T1 values were also higher in the MI zone surrounding areas of residual myocardial iron compared with those without, this difference in T1 may have been because of the complex interplay between fibrosis, edema, and the development of early fatty metaplasia in the chronic phase of a STEMI.

It is well recognized that IMH is associated with larger MI size, adverse LV remodeling, and poor clinical outcomes and may be proarrhythmic. Although our study was purely based on tissue characterization, these findings support the current literature that residual myocardial iron may play a role in the inflammatory phase of adverse LV remodeling. Using T2* imaging, Kali et al have recently shown in a small cohort of 15 STEMI patients that the presence of IMH on the acute CMR scans was associated with residual myocardial iron at 6 months. They also used immunohistochemical analysis of canine hearts subjected to acute MI to show evidence of localized accumulation of macrophages at the sites of chronic iron deposition at follow-up, suggesting a prolonged inflammatory response at the sites of residual myocardial iron. Roghi et al also showed in a small cohort of 15 STEMI patients that those with MVO and IMH had higher levels of nontransferrin-bound iron—these have previously been linked to cardiotoxicity in thalassemia major. Our study is the first study to use T2 mapping for the detection of delayed resolution of edema associated with residual myocardial iron in patients with IMH.

Recently, Carrick et al performed serial scanning in 30 patients and elegantly described the time course of MVO and IMH. MVO was already present at 4 to 12 hours and remained stable up to a mean of 2.9 days and then reduced by day 10. IMH, on the contrary, peaked at a mean of 2.9 days and decreased by day 10. Of note, 13 patients had IMH on day 2.9, and only 4 patients displayed residual myocardial iron by 6 months. Based on brain imaging data, degradation of hemoglobin eventually leads to ferritin and hemosiderin deposits, and the fact that the majority of their patients had no residual iron in the acute phase, but some had residual iron at 6 months would suggest that the iron was not bound to transferrin and was therefore present in hemosiderin deposits.
myocardial iron in their study may suggest that those patients had small areas of IMH that were rapidly cleared by the macrophages. They reported the presence of IMH in 41% of their total cohort of 245 patients with analyzable T2* data, and it is likely that they may have underestimated the true prevalence of IMH because the CMR was performed at a mean of 2.1 days and some patients who would have subsequently developed IMH up to 3 days post reperfusion may not have been detected.

Pooling the results of these 3 studies demonstrating residual myocardial iron after STEMI, Kali et al.15 (acute scan: 11 out of 15 patients with IMH; follow-up scan: 11 with residual myocardial iron), Carrick et al.34 (acute scan: 13 out of 30 patients with IMH; follow-up scan: 4 with residual myocardial iron), and our study (acute scan: 15 out of 28 patients with IMH; follow-up scan: 13 with residual myocardial iron), the prevalence of IMH by T2* mapping was 53% (39/73), and 72% (28/39) had residual myocardial iron at follow-up. Although IMH is likely to be confounded by larger infarct size, whether specifically targeting these patients with anti-inflammatory agents or chelation therapy needs to be investigated in further studies aiming to prevent adverse LV remodeling.

Limitations
A significant proportion of the T2* maps were not interpretable in our study, and this partly highlights the challenge of performing a comprehensive CMR scan with multiparametric mapping in patients with an acute STEMI and may be partly because of the suboptimal per-slice rather than whole-heart shimming protocol we used. Of note, 18% of T2* data were not available in the large study by Carrick et al.34 either because of patients’ intolerance of the scan or non-interpretable T2* maps. Although we quantified the extent of IMH in our study, we only used basal, mid, and apical short-axis T2* maps, and the quantification may have been more accurate if whole LV coverage T2* maps had been performed. Furthermore, only basal, mid, and apical short-axis T1 and T2 maps were acquired at follow-up. We used 2 different LGE sequences, and the difference in signal-to-noise ratio between the 2 may have affected the MVO size quantification. LGE images were acquired between 10 and 15 minutes, and this may have overestimated the MI and MVO size, and whether acquiring LGE images at 25 minutes would have yielded different diagnostic performances for LGE, MVO, and IMH to predict adverse LV remodeling warrants further investigation. Receiver operating characteristic curve analysis was performed in 28 patients only, and therefore, we did not provide data on sensitivity/specificity and cutoff values because of small sample size. We did not measure blood inflammation markers to support the proposal of persistent inflammation because of residual myocardial iron in these patients. Histological validation is required to determine whether the elevated T2 values in the myocardium surrounding residual iron in the infarct zone was because of persistent inflammation. Our study was small, and we could not establish a causal relationship between IMH and adverse LV remodeling.

Conclusion
The majority of reperfused STEMI patients with IMH had residual myocardial iron at follow-up. This was associated with adverse LV remodeling and persistently elevated T2 values in the surrounding infarct tissue and may be suggestive of ongoing inflammation. Furthermore, IMH was as strongly associated with adverse LV remodeling as acute MI size and MVO. Therefore, patients with IMH or residual myocardial iron could be future potential targets for therapeutic interventions with anti-inflammatory agents or chelation therapy aiming to prevent adverse LV remodeling and improve clinical outcomes in these patients.
Acknowledgments
We express our gratitude to the work in progress investigation, for their support.

Sources of Funding
This work was supported by the British Heart Foundation (FS/10/039/28270), the Rosetrees Trust, and the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

Disclosures
None.

References

5 Bulluck et al. Residual Iron in STEMI and Adverse LV Remodeling

17. Bulluck et al. Residual Iron in STEMI and Adverse LV Remodeling

5 Bulluck et al. Residual Iron in STEMI and Adverse LV Remodeling

17. Bulluck et al. Residual Iron in STEMI and Adverse LV Remodeling

5 Bulluck et al. Residual Iron in STEMI and Adverse LV Remodeling

It is already known that ≈50% of ST-segment–elevation myocardial infarction patients develop microvascular obstruction, despite prompt reperfusion of the epicardial vessel by primary percutaneous coronary intervention, and this is associated with adverse left ventricular remodeling and worse clinical outcomes. However, the impact of intramyocardial hemorrhage on the same end points has not been clearly established. Our study analyzed paired cardiovascular magnetic resonance scans in 40 ST-segment–elevation myocardial infarction patients within 1 week and at 5 months after primary percutaneous coronary intervention. Twenty-eight patients also had paired T2* mapping data available. We found that the large majority (83%) of the patients with microvascular obstruction also had intramyocardial hemorrhage. Many of these patients went on to have residual myocardial iron at follow-up (87%) as identified by T2* mapping, and this was associated with persistently elevated T2 values in the surrounding infarct tissue. Furthermore, intramyocardial hemorrhage was as strongly associated with adverse left ventricular remodeling as acute myocardial infarction size and microvascular obstruction. These findings suggest that intramyocardial hemorrhage and residual iron within the infarct zone may be associated with delayed resolution of edema or inflammation and adverse left ventricular remodeling. Therefore, whether anti-inflammatory agents or iron chelation therapy may prevent adverse left ventricular remodeling and improve clinical outcomes in ST-segment–elevation myocardial infarction patients treated by primary percutaneous coronary intervention warrants further investigation.
Residual Myocardial Iron Following Intramyocardial Hemorrhage During the Convalescent Phase of Reperfused ST-Segment-Elevation Myocardial Infarction and Adverse Left Ventricular Remodeling

Heerajnarain Bulluck, Stefania Rosmini, Amna Abdel-Gadir, Steven K. White, Anish N. Bhuva, Thomas A. Treibel, Marianna Fontana, Manish Ramlall, Ashraf Hamarneh, Alex Sirker, Anna S. Herrey, Charlotte Manisty, Derek M. Yellon, Peter Kellman, James C. Moon and Derek J. Hausenloy

_Circ Cardiovasc Imaging_. 2016;9:
doi: 10.1161/CIRCIMAGING.116.004940
_Circulation: Cardiovascular Imaging_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-9651. Online ISSN: 1942-0080

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circimaging.ahajournals.org/content/9/10/e004940
Free via Open Access

Data Supplement (unedited) at:
http://circimaging.ahajournals.org/content/suppl/2016/10/10/CIRCIMAGING.116.004940.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation: Cardiovascular Imaging_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation: Cardiovascular Imaging_ is online at:
http://circimaging.ahajournals.org//subscriptions/
CONSORT flow diagram: illustration of number of patients recruited and scanned at the 2 time-points.
Supplemental Table: CMR characteristics patients with and without paired T2* maps

<table>
<thead>
<tr>
<th></th>
<th>Patients with paired T2* maps (n=28)</th>
<th>Patients without paired T2* maps (n=12)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>EDV/ml</td>
<td>173±40</td>
<td>170±31</td>
<td>0.79</td>
</tr>
<tr>
<td>ESV/ml</td>
<td>91±32</td>
<td>87±24</td>
<td>0.71</td>
</tr>
<tr>
<td>EF/%</td>
<td>48±9</td>
<td>50±7</td>
<td>0.58</td>
</tr>
<tr>
<td>Mass/ g</td>
<td>119±33</td>
<td>104±24</td>
<td>0.15</td>
</tr>
<tr>
<td>Change in EDV/ ml</td>
<td>7±16</td>
<td>3±13</td>
<td>0.44</td>
</tr>
<tr>
<td>Acute infarct size/ %LV</td>
<td>26.7±15.2</td>
<td>28.8±13.6</td>
<td>0.69</td>
</tr>
<tr>
<td>Follow-up Infarct size/ %LV</td>
<td>18.5±11.1</td>
<td>22.0±9.8</td>
<td>0.36</td>
</tr>
<tr>
<td>T2-based AAR/ % of LV</td>
<td>42.7±12.3</td>
<td>40.3±11.8</td>
<td>0.56</td>
</tr>
<tr>
<td>MVO/ n (%)</td>
<td>18 (64)</td>
<td>8 (67%)</td>
<td>0.59</td>
</tr>
<tr>
<td>Adverse LV remodeling/ n (%)</td>
<td>6 (21%)</td>
<td>2 (17%)</td>
<td>0.55</td>
</tr>
<tr>
<td>Acute scan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T2&lt;sub&gt;Remote&lt;/sub&gt;</td>
<td>50 (48-52)</td>
<td>50 (48-52)</td>
<td>0.85</td>
</tr>
<tr>
<td>T2&lt;sub&gt;Core&lt;/sub&gt;</td>
<td>52 (48-55)</td>
<td>51 (48-54)</td>
<td>0.96</td>
</tr>
<tr>
<td>T2&lt;sub&gt;Infarct&lt;/sub&gt;</td>
<td>64 (62-68)</td>
<td>65 (64-66)</td>
<td>0.80</td>
</tr>
<tr>
<td>Follow-up scan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T2&lt;sub&gt;Remote&lt;/sub&gt;</td>
<td>48 (46-50)</td>
<td>47 (45-49)</td>
<td>0.63</td>
</tr>
<tr>
<td>T2&lt;sub&gt;Core&lt;/sub&gt;</td>
<td>47 (45-49)</td>
<td>47 (46-48)</td>
<td>0.90</td>
</tr>
<tr>
<td>T2&lt;sub&gt;Infarct&lt;/sub&gt;</td>
<td>57 (53-61)</td>
<td>54 (52-57)</td>
<td>0.25</td>
</tr>
</tbody>
</table>